ImaginAb’s imaging products have the potential to deliver fundamentally new insights into patient selection and treatment progress for immuno-oncology therapies.
Preclinical and Clinical data demonstrate ImaginAb’s immune imaging technology safely targets and binds to cytotoxic CD8 T cells—the key immune cells that must be present in meaningful quantities for immunotherapy to be effective.
Used in conjunction with Positron Emission Tomography (PET), our tools provide an actionable picture of immune response to inform therapy decisions.
This noninvasive imaging approach has been validated across several pharmaceutical-partnered immune programs and through our proprietary imaging program for CD8 T cells, currently in Phase 2 clinical trials. It’s also championed by oncology thought leaders who share in our vision to provide a more accurate tool for guiding the course of immuno-oncology treatment.